| Field | Specification |
|---|---|
| Mfr No | |
| Clonality | |
| Host | |
| Immunogen | A recombinant fragment from the human protein corresponding to the N-terminal region was used as the immunogen for the recombinant CD2 antibody. |
| Isotype | |
| Product Type | |
| Purity | |
| Reactivity | |
| Storage | |
| Target | |
| UniProt # |
Overview
Recombinant CD2 Antibody / Lymphocyte Function Antigen 2 / LFA-2 is an antibody targeting CD2. Host: Mouse. Monoclonal. Clone: rLFA2/7147. Format: Purified. Applications: IHC-P.
Key elements and design rationale
- Target: CD2.
- Immunogen: A recombinant fragment from the human protein corresponding to the N-terminal region was used as the immunogen for the….
- Species reactivity: Human.
- Localization: Cell surface.
- Conjugate: Unconjugated (no label listed).
Biological background (from provided description)
CD2 interacts with lymphocyte function-associated antigen CD58 (LFA-3) and CD48/BCM1 to mediate adhesion between T-cells and other cell types. [UniProt]
Common research applications
- IHC: tissue distribution assessment; interpret with matched controls.
Notes for experimental interpretation
- Account for isoforms, paralogs, and post-translational modifications when interpreting signal.
- Support specificity with biological controls (e.g., KO/KD where available) and technical controls (e.g., secondary-only/isotype).
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
